IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

MORA, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.857
EU - Europa 1.150
AS - Asia 1.024
Continente sconosciuto - Info sul continente non disponibili 101
SA - Sud America 95
AF - Africa 17
OC - Oceania 2
Totale 5.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.810
IT - Italia 541
SG - Singapore 382
CN - Cina 183
VN - Vietnam 159
UA - Ucraina 137
HK - Hong Kong 111
SE - Svezia 105
TR - Turchia 93
BR - Brasile 78
IE - Irlanda 67
DE - Germania 65
GB - Regno Unito 64
FR - Francia 41
BD - Bangladesh 34
FI - Finlandia 32
RU - Federazione Russa 31
CA - Canada 30
IN - India 17
JP - Giappone 16
MX - Messico 12
PL - Polonia 12
CZ - Repubblica Ceca 10
NL - Olanda 10
ZA - Sudafrica 10
ES - Italia 8
AR - Argentina 6
LT - Lituania 6
PK - Pakistan 6
BE - Belgio 5
AT - Austria 4
CL - Cile 4
KE - Kenya 3
MD - Moldavia 3
SA - Arabia Saudita 3
TH - Thailandia 3
UZ - Uzbekistan 3
VE - Venezuela 3
EC - Ecuador 2
GR - Grecia 2
HU - Ungheria 2
IQ - Iraq 2
KR - Corea 2
KZ - Kazakistan 2
MY - Malesia 2
NG - Nigeria 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CH - Svizzera 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
EU - Europa 1
GT - Guatemala 1
HN - Honduras 1
ID - Indonesia 1
JM - Giamaica 1
LB - Libano 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
TN - Tunisia 1
TW - Taiwan 1
Totale 5.146
Salva come PNG Salva come JPEG
Città #
Milan 377
Fairfield 323
Ashburn 262
Woodbridge 226
Singapore 208
San Jose 175
Houston 165
Seattle 151
Chandler 150
Jacksonville 121
Wilmington 121
Cambridge 117
Ann Arbor 113
Hong Kong 106
Nyköping 77
Dallas 72
Princeton 65
Dublin 64
Izmir 48
The Dalles 44
Beijing 43
Boardman 43
Dearborn 38
Council Bluffs 35
Lauterbourg 34
Dong Ket 33
San Diego 31
Los Angeles 28
Hanoi 27
Ho Chi Minh City 25
New York 23
Rome 23
Como 22
London 21
Ogden 20
Santa Clara 20
Helsinki 18
Redmond 18
Orem 16
Chicago 13
Kocaeli 13
Munich 13
São Paulo 13
Toronto 13
Tokyo 12
Atlanta 11
Warsaw 11
Brno 9
Brooklyn 9
Johannesburg 9
Mexico City 9
Frankfurt am Main 8
Poplar 8
San Francisco 8
Washington 8
Amsterdam 7
Varese 7
Chennai 6
Columbus 6
Denver 6
Manchester 6
Montreal 6
Shanghai 6
Ankara 5
Brussels 5
Dhaka 5
Guangzhou 5
Haiphong 5
Hefei 5
Miami 5
Rio de Janeiro 5
City of London 4
Da Nang 4
Falkenstein 4
Ha Long 4
Hangzhou 4
Jackson 4
Kilburn 4
Kunming 4
Ottawa 4
Phoenix 4
Redwood City 4
Cavaria con Premezzo 3
Concord 3
Gavirate 3
Islamabad 3
Mumbai 3
Nairobi 3
Nanchang 3
Nanjing 3
Norwalk 3
Nuremberg 3
Salt Lake City 3
Stockholm 3
Tashkent 3
Zhengzhou 3
Alvorada 2
Astana 2
Belo Horizonte 2
Biên Hòa 2
Totale 3.854
Salva come PNG Salva come JPEG
Nome #
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts 249
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 247
Looking for CALR mutations in familial myeloproliferative neoplasms 224
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion 219
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 218
It is time to change thrombosis risk assessment for PV and ET? 202
Developments in diagnosis and treatment of essential thrombocythemia 201
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 200
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients 198
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group 198
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis 172
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms 171
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation 169
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia 147
Prognostication in myelofi-brosis 143
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients 143
Therapy of polycythemia vera: Is it time to change? 137
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 133
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 129
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 127
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches 123
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection 123
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 121
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis 121
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma 119
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 115
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses 113
Is there a gender effect in polycythemia vera? 106
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 104
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 98
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 96
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence 87
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi 82
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 74
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 72
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 65
Totale 5.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.534
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.534
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022281 0 16 2 15 11 22 16 21 26 87 19 46
2022/2023473 33 13 75 43 36 102 2 56 75 13 9 16
2023/2024618 91 94 92 115 133 40 7 4 25 2 5 10
2024/2025555 15 3 79 43 23 25 18 54 84 49 42 120
2025/20261.305 106 87 70 229 132 83 245 71 129 82 54 17
2026/2027101 37 64 0 0 0 0 0 0 0 0 0 0
Totale 5.246